Trial Profile
A prospective, open, randomized, phase-II study of a therapeutic cancer vaccine (L-BLP25, Stimuvax) in the pre-operative treatment of women with primary breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2022
Price :
$35
*
At a glance
- Drugs Tecemotide (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Letrozole
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms ABCSG-34
- 03 Dec 2021 Results published in the Clinical Cancer Research
- 04 Jun 2020 EndoPredict test results published in the Myriad Genetics Media Release.
- 04 Jun 2020 According to an Myriad Genetics, Inc media release, the company announced the publication of a prospective study demonstrating that the EndoPredict test predicts which patients with ER+, HER2- early-stage breast cancer will benefit from neoadjuvant therapy in the European Journal of Cancer. The test prediction is based on the patients from the ABCSG-34 trial. Peter Dubsky is the lead author, speaking on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).